Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-Label, Phase 1, Single- and Multiple Ascending Dose Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (nAMD).

Next Previous
X
Search
Trial Profile

A Multi-center, Open-Label, Phase 1, Single- and Multiple Ascending Dose Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (nAMD).

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PMC-403 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors PharmAbcine

    • Most Recent Events

    • 04 Dec 2023 According to PharmAbcine Media Release, the Korea Drug Development Fund (KDDF) to fund the Phase 1 clinical study for patients with neovascular age-related macular degeneration (nAMD) in Korea for 2 years.
    • 09 Nov 2023 According to PharmAbcine Media Release, company announced that the Safety Review Committee (SRC) has approved advancing to dose level 2 of the PMC-403 Phase 1 clinical study in neovascular age-related macular degeneration patients following completion of dose level 1 safety data evaluation.
    • 26 Jul 2023 According to PharmAbcine Media Release, first patient had been dosed in this trial and study, is currently enrolling patients at multiple hospitals in South Korea, including Seoul National University Bundang Hospital.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top